Search
Pomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Products: POMALYST 1 MG, POMALYST 2 MGZolmitriptan
go.drugbank.com/drugs/DB00315ApprovedInvestigationalIt is currently available in both tablet and nasal spray forms.[L12978] … [A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment.
Products: Zomig 5 mg Nasenspray, Zomig 2,5 mg NasensprayMavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalIt received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]
Products: Camzyos 5 mg Sert Kapsül (14 adet), Camzyos 2,5 mg Sert Kapsül (14 adet)Buspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigational[A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®. … [L7375] The potential use of buspirone in combination with [melatonin] in depression and cognitive impairment via promoting neurogenesis has also been investigated.[A181751]
Products: NOPIRON 5 MG TABLET, 100 ADET, NOPIRON 10 MG TABLET, 100 ADETAxitinib
go.drugbank.com/drugs/DB06626ApprovedInvestigational[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Synonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamideProducts: INLYTA (TABLETS 1 MG), INLYTA (TABLETS 5 MG)Trametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigational[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. … [L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a
Products: MEKINIST (TABLETS 2 MG), MEKINIST (TABLETS 0.5 MG)Palbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalPalbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male
Products: REAMPLA 100 MG KAPSÜL, 7 KAPSÜL, REAMPLA 100 MG KAPSÜL, 21 KAPSÜLMonobenzone
go.drugbank.com/drugs/DB00600ApprovedWithdrawnMonobenzone occurs as a white, almost tasteless crystalline powder, soluble in alcohol and practically insoluble in water. … It exerts a depigmenting effect on skin of mammals by increasing the excretion of melanin from the melanocytes. It may also cause destruction of melanocytes and permanent depigmentation.
Products: Benoquin Crm 20%, MONOTONE %20 KREM, 113,5 GRAnagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Products: ANAGLYN 0,5 MG SERT KAPSÜL, 100 KAPSÜL, GRAFTA 0.5 MG SERT KAPSÜL, 100 ADETFerric hydroxide
go.drugbank.com/drugs/DB13423InvestigationalProducts: FERIFER 100 MG/5 ML ORAL COZELTI ICEREN KAŞIK, 20 ADET, FERIFER 100 MG/5 ML ORAL COZELTI ICEREN 10 KASIK